Target Overview & Key Facts
Integrin beta-6 (ITGB6) is the beta subunit of the integrin αvβ6, encoded by the ITGB6 gene, UniProt entry P18564. The protein contains three major functional domains: PSI (involved in disulfide bond formation), VWFA (ligand-binding domain), and I-EGF 1 (epidermal growth factor-like domain). Key mutations located in the AI1H region include rs140015315, rs730880298, and rs730882118 (UniProt VAR_073328-073330). ITGB6 must heterodimerize with integrin αV (ITGAV) to be functional. It is minimally expressed in healthy adult tissues but highly upregulated in epithelial injury, fibrosis, and multiple solid tumors, making it an ideal target for anti-fibrotic and anti-cancer drug development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ITGB6 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ITGB6 ECD-Fc Fusion Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. HEK293 Expressed (Native Glycosylation). Sequence Verified. |
View ITGB6 Products |
| Gene Delivery | ITGB6 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell lines. Co-expression with ITGAV required for functional heterodimer formation. |
View ITGB6 Products |
| Benchmark Ab | Anti-ITGB6 (Clinical Biosimilar Sequence) Recombinant positive control for binding and blocking assays. |
View ITGB6 Products |
| Validator | ITGB6 siRNA Set For knockdown verification and specificity controls. |
View ITGB6 Products |
| Heterodimer Partner | ITGAV (Integrin alpha-V) Essential binding partner for functional αvβ6 integrin complex formation. |
View ITGAV Products |
| Selectivity Control | ITGB8 (Integrin beta-8) Highly homologous alphav-binding integrin for counter-screening assays. |
View ITGB8 Products |
| Pathway Target | TGFB1 Downstream cytokine activated by ITGB6-mediated LAP binding. |
View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Cyno/Mouse ITGB6 ortholog proteins available with >95% purity, Sequence Verified |
| Heterodimer functional validation | ITGAV Lentivirus particles for stable co-expression cell line construction; co-expressed and purified heterodimer complexes available, verified by mass spec and SEC-HPLC |
| Subfamily counter screening (β1/β3/β5/β8) | Homolog panel proteins (ITGB1, ITGB3, ITGB5, ITGB8) strictly verified by mass spec for selectivity assays |
| Internalization efficiency (ADC development) | High-purity ECD-Fc with native conformation for pH-dependent binding studies |
| False positives / target engagement | Sequence-verified siRNA included for specificity checks and target validation |
| Lack of controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization |
Global Clinical Landscape & Future Outlook
The race for ITGB6-targeted therapeutics is intensifying, with major players shifting focus from pan-αv inhibitors to selective β6-targeting modalities. First-generation small molecules (dual αvβ6/αvβ1), such as PLN-74809 from Pliant Therapeutics, have reached Phase 2 for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), with additional exploration in non-alcoholic steatohepatitis (NASH). In oncology, antibody-drug conjugates (ADCs) have become the dominant strategy, leveraging ITGB6's high expression and efficient internalization in pancreatic ductal adenocarcinoma, head and neck squamous cell carcinoma, and ovarian cancer. Key players include Seagen (Pfizer) and Mersana. On the antibody front, Biogen's STX-100 (discontinued) was evaluated in IPF, while MorphoSys and AbbVie have active programs. Bispecific antibodies are in early development. Future directions include combination with PD-1/PD-L1 inhibitors to reverse TGF-β-mediated immune suppression, and co-administration with existing anti-fibrotic agents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Dual αvβ6/αvβ1) | Pliant Therapeutics, Bristol Myers Squibb | IPF, PSC, NASH | Selectivity Assay (Need ITGB6 vs ITGB1 mutant proteins for discriminating binding) |
| ADC | Seagen (Pfizer), Mersana, Emerging Preclinical Programs | Solid Tumors (Pancreatic, Ovarian, HNSCC) | Internalization Assay (Need high-purity heterodimer ECD-Fc for endocytosis confirmation) |
| Monoclonal Antibody | Biogen (Discontinued STX-100), MorphoSys, AbbVie | Fibrosis (IPF) | Heterodimer Validation (Need ITGAV co-expression for native conformation binding) |
| Bispecific | Early Development | Fibrosis/Oncology | Cross-reactive Abs (Human/Cyno/Rat binding verification) |
Molecular Differentiation Needs & Assay Strategies
Developing best-in-class ITGB6-targeted drugs requires addressing five major differentiation challenges:
- Subtype Selectivity: The αv integrin family includes β1, β3, β5, β6, β8. αvβ1 shares high sequence homology with αvβ6 and overlapping LAP binding. Use ITGB1, ITGB8 control proteins in SPR/BLI to confirm >100-fold selectivity window.
- Heterodimer Integrity: Monomeric ITGB6 is non-functional. Co-express ITGAV to generate stable cell lines for conformation-dependent screening.
- Internalization Efficiency: Different epitopes exhibit distinct internalization kinetics. Use high-purity ECD-Fc for pH-dependent binding studies (pH 7.4 vs pH 5.0) to predict lysosomal release.
- Cross-species Reactivity: Preclinical tox requires human, cynomolgus, and rodent models. TarMart provides multi-species ortholog proteins.
- TGF-β Activation Blockade vs Adhesion Retention: Competitive ELISA using biotinylated LAP vs fibronectin to differentiate inhibition profiles.
TarMart solutions: HEK293 expression ensures proper folding and disulfide bonds; lentivirus co-expression enables functional cell lines; mutant proteins support conformation-selective screening; siRNA sets enable on-target verification.
Related Target Recommendations
- ITGAV (CD51): Obligate heterodimer partner. Lentivirus and recombinant proteins available.
- ITGB8: Selectivity control; avoid αvβ8 inhibition linked to CNS vascular malformations.
- TGFB1 (TGF-β1): Downstream effector; used in functional reporter assays.
- ITGB1 / ITGB3 / ITGB5: Family proteins for counter-screening.